Radiolabeled Benzamide Derivatives for Development of Malignant Melanoma Imaging AgentsRadiolabeled Benzamide Derivatives for Development of Malignant Melanoma Imaging Agents
- Other Titles
- Radiolabeled Benzamide Derivatives for Development of Malignant Melanoma Imaging Agents
- Authors
- 표아영; 송보름; 김희정; 김동연
- Issue Date
- 2022
- Publisher
- 대한방사성의약품학회
- Keywords
- Benzamide derivatives; Malignant melanoma; Melanin; Positron emission tomography; Molecular imaging
- Citation
- 대한방사성의약품학회지, v.8, no.1, pp 25 - 31
- Pages
- 7
- Indexed
- KCI
- Journal Title
- 대한방사성의약품학회지
- Volume
- 8
- Number
- 1
- Start Page
- 25
- End Page
- 31
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/2256
- ISSN
- 2384-1583
- Abstract
- Malignant melanoma has an aggressive nature and high metastatic potential that result in one of the highest cancer mortality rates. Over the past three decades, primary and metastatic melanoma incidence has rapidly increased. The recent advances in diagnostic technology have shown promise, but there is still an enormous need for specific detection methods to diagnose malignant melanoma. Positron emission tomography can visualize a particular biomarker of malignant melanoma and promise a noninvasive image of micrometastases. However, the development of PET radiopharmaceuticals remains necessary for diagnosing malignant melanoma by using positron emission tomography. In this review, the history and a general overview of PET radionuclide labeled benzamide derivatives, including their radiosynthesis, in vivo characterization, and evaluation, are provided as imaging agents for malignant melanoma.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.